DEYZOLY Trademark
DEYZOLY is a USPTO trademark filed by Zealand Pharma A/S. Status: Pending.
Trademark Facts
| Mark | DEYZOLY |
|---|---|
| Serial Number | 79446709 |
| Status | Pending |
| Filing Date | 2025-11-27 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals), 010 (Medical Devices), 044 (Medical Services) |
| Owner | Zealand Pharma A/S |
| Prosecution Events | 6 |
| Latest Event | RFCR on 2026-04-09 |
Goods & Services
Class 005: Pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); pharmaceutical preparations, namely for treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia; medical preparations for the treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.; Class 010: Devices for introducing pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS), and parts and fittings therefor; devices for introducing pharmaceutical preparations, namely for treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia, and parts and fittings therefor.; Class 044: Medical and pharmaceutical services, namely in relation to treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical and pharmaceutical advice, namely in relation to treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical and pharmaceutical services, namely in relation to treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia; medical and pharmaceutical advice, namely in relation to treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.